Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Oncotarget · 2017 · PMC5362453 · PMID 28107181

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In addition to the different distribution of subtypes in IBC, when we evaluated freedom-from-recurrence as a function of cyclin E phenotype, we found that cyclin E phenotype did not predict outcome in IBC, in contrast to the highly significant correlation between cytoplasmic cyclin E and poorer outcome in the non-IBC cohort.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.